Cargando…

Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK

OBJECTIVES: Budesonide/formoterol (BF) Spiromax(®) is an inhaled corticosteroid/long-acting β(2)-agonist fixed-dose combination (FDC) inhaler, designed to minimise common inhaler errors and provide reliable and consistent dose delivery in asthma and chronic obstructive pulmonary disease (COPD). We e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voorham, Jaco, Roche, Nicolas, Benhaddi, Hicham, van der Tol, Marianka, Carter, Victoria, van Boven, Job F.M., Bjermer, Leif, Miravitlles, Marc, Price, David B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Respiratory Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224753/ https://www.ncbi.nlm.nih.gov/pubmed/30368448 http://dx.doi.org/10.1136/bmjopen-2018-022051

Ejemplares similares

Real-world evidence effect of budesonide+formoterol Spiromax on patients with asthma and chronic obstructive pulmonary disease in Sweden
por: Janson, Christer, et al.
Publicado: (2019)

Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study
por: Price, David B., et al.
Publicado: (2018)

Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
Publicado: (2019)

Correction: Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK
Publicado: (2018)

A randomized, double-blinded, double-dummy efficacy and safety study of budesonide–formoterol Spiromax® compared to budesonide–formoterol Turbuhaler® in adults and adolescents with persistent asthma
por: Virchow, J. Christian, et al.
Publicado: (2016)

A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management
por: Louis, R, et al.
Publicado: (2009)

Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction
por: Lazarinis, Nikolaos, et al.
Publicado: (2014)

Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study
por: Voorham, Jaco, et al.
Publicado: (2017)

Historical database cohort study addressing the clinical patterns prior to idiopathic pulmonary fibrosis (IPF) diagnosis in UK primary care
por: Thickett, David, et al.
Publicado: (2020)

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma
por: Morice, A H, et al.
Publicado: (2007)

A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler(®) to Budesonide/Formoterol Easyhaler(®)
por: Syk, Jörgen, et al.
Publicado: (2019)

Evaluation of inhaler handling-errors, inhaler perception and preference with Spiromax, Easyhaler and Turbuhaler devices among healthy Finnish volunteers: a single site, single visit crossover study (Finhaler)
por: Sandler, Niklas, et al.
Publicado: (2016)

Comparative Efficacy of Budesonide/Formoterol with Budesonide, Formoterol or Placebo for Stable Chronic Obstructive Pulmonary Disease: A Meta-Analysis
por: Tang, Bin, et al.
Publicado: (2019)

Correction to: A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler(®) to Budesonide/Formoterol Easyhaler(®)
por: Syk, Jörgen, et al.
Publicado: (2019)

Budesonide–formoterol (inhalation powder) in the treatment of COPD
por: Ceylan, Erkan
Publicado: (2006)

Comparison of Aerosol Formulations of Formoterol Fumarate and Budesonide
por: Nirale, N. M., et al.
Publicado: (2011)

Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Protocol: Influence of Budesonide and Budesonide/Formoterol on Asthma Control in Smoking Asthmatic Adults
por: Boulet, Louis-Philippe, et al.
Publicado: (2010)

Budesonide/formoterol combination in COPD: a US perspective
por: Sharafkhaneh, Amir, et al.
Publicado: (2010)

Tolerability of budesonide/formoterol in patients of Kazakhstan rural regions
por: Nurpeissov, Tair, et al.
Publicado: (2015)

Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Comparison of correct technique and preference for Spiromax®, Easyhaler® and Turbuhaler®: a single-site, single-visit, crossover study in inhaler-naïve adult volunteers
por: Rönmark, Per, et al.
Publicado: (2018)

Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats
por: Salazar-Degracia, Anna, et al.
Publicado: (2017)

Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol
por: Bateman, ED, et al.
Publicado: (2006)

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations
por: Kuna, P, et al.
Publicado: (2007)

Effect of adjusting the combination of budesonide/formoterol on the alleviation of asthma symptoms
por: Souma, Ryosuke, et al.
Publicado: (2018)

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Guo, Min, et al.
Publicado: (2022)

Budesonide and formoterol effects on rhinovirus replication and epithelial cell cytokine responses
por: Bochkov, Yury A, et al.
Publicado: (2013)

The rapid effects of budesonide plus formoterol in patients with obstructive airway diseases
por: Bayiz, Hulya, et al.
Publicado: (2015)

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
por: Calverley, Peter M, et al.
Publicado: (2016)

Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis
por: Tang, Bin, et al.
Publicado: (2019)

Retracted: The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids
por: van den Berge, Maarten, et al.
Publicado: (2021)

Bronchodilatory effect of inhaled budesonide/formoterol and budesonide/salbutamol in acute asthma: a double-blind, randomized controlled trial
por: Arun, Jenish J, et al.
Publicado: (2012)

Budesonide and Formoterol Reduce Early Innate Anti-Viral Immune Responses In Vitro
por: Davies, Janet M., et al.
Publicado: (2011)

Long-term maintenance of pediatric asthma: focus on budesonide/formoterol inhalation aerosol
por: Huynh, Peter N, et al.
Publicado: (2010)

Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma
por: KAGOHASHI, KATSUNORI, et al.
Publicado: (2014)

Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study
por: Ferguson, Gary T., et al.
Publicado: (2018)

Can electronic monitoring with a digital smart spacer support personalised medication adherence and inhaler technique education in patients with asthma?: Protocol of the randomised controlled OUTERSPACE trial
por: Dierick, Boudewijn H.J., et al.
Publicado: (2022)

In patients with severe uncontrolled asthma, does knowledge of adherence and inhaler technique using electronic monitoring improve clinical decision making? A protocol for a randomised controlled trial
por: Mokoka, Matshediso C, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_orccnnfinju2khktfkbvp2br25